AmplifyBio, a Contract Development and Manufacturing Organization and Contract Research Organization, and RNAV8 Bio, a rising startup specializing in mRNA engineering platforms, have collaborated to provide a comprehensive solution for mRNA therapeutics development. This partnership aims to tackle a significant challenge hindering the full therapeutic potential of mRNA across various diseases: the absence of an efficient infrastructure for rapid development and production.

"Current hurdles in mRNA therapeutics development stem from fragmented processes and limited access to advanced technologies," stated Devan Shah, CEO at RNAV8 Bio. Shah highlighted the struggle for incumbents in establishing effective mRNA design and manufacturing teams amidst disjointed supply chains. RNAV8 Bio's expertise lies in leveraging rational design and cutting-edge ML/AI methods to engineer mRNA functionalities more precisely.

By integrating RNAV8's mRNA design proficiency with AmplifyBio's robust preclinical and manufacturing capabilities, the partnership offers a streamlined approach to mRNA development and scale-up. J. Kelly Ganjei, CEO at AmplifyBio, expressed enthusiasm for the synergies between the two entities, emphasizing the potential for rapid iterative development and testing within their integrated infrastructure.

The collaboration establishes a unified platform for mRNA sequence/chemistry engineering, in vitro screening, in vivo model data generation, and mRNA production across various scales. RNAV8 Bio, comprising experts from esteemed backgrounds, including Moderna and Pfizer, brings a novel approach to mRNA engineering, promising enhanced expression compared to conventional methods.

In essence, the partnership between AmplifyBio and RNAV8 Bio represents a significant step towards addressing the challenges in mRNA therapeutics development, offering a cohesive solution to expedite the translation of mRNA innovations into clinical reality.

 

Source: amplify-bio.com

Report Abuse